Literature DB >> 31390635

Distribution of Neuroendocrine Marker-Positive Cells in Colorectal Cancer Tissue and Normal Mucosal Tissue: Consideration of Histogenesis of Neuroendocrine Cancer.

Takashi Ogimi1, Sotaro Sadahiro2, Yutaro Kamei1, Lin Fung Chan1, Hiroshi Miyakita1, Gota Saito1, Kazutake Okada1, Toshiyuki Suzuki1, Hiroshi Kajiwara3.   

Abstract

BACKGROUND: Colorectal neuroendocrine carcinoma (NEC) is a rare disease, and mixed cases with colorectal adenocarcinoma also exist. The histogenesis of this disease remains unclear. We studied the numbers of neuroendocrine marker-positive cells in adenocarcinoma tissue and in normal -mucosal tissue to investigate the relation between adenocarcinoma and NEC and to discuss the histogenesis of NEC.
METHODS: We studied a total of 354 curatively resected cases of stage II or III colon cancer and 36 cases of rectal cancer treated at the Tokai University Hospital between 2007 and 2012. Adenocarcinoma tissue and normal mucosal tissue were immunohistochemically stained with chromogranin A, synaptophysin, and CD56. Cases in which neuroendocrine marker-positive cells were found in cancer tissue were defined as positive. In normal mucosa, the numbers of positive cells per 15 high-power fields (HPF) were counted.
RESULTS: Among the 390 cases, 181 cases had right sided colon cancer, 173 cases had left sided colon cancer, and 36 cases had rectal cancer. The rates of positive staining for chromogranin A, synaptophysin, and CD56 were significantly higher in the right sided colon than in the left sided colon, consistent with the preferred sites of NEC as reported previously. Cells positive for chromogranin A and synaptophysin in normal mucosa were significantly more common in the rectum and the left sided colon than in the right sided colon. No site-specific differences were found for CD56.
CONCLUSIONS: Neuroendocrine marker-positive cells in colorectal cancer tissue are more common in the right sided colon, whereas neuroendocrine marker-positive cells in normal mucosa are more common in the rectum. These results suggest that NEC may arise from preceding adenocarcinomas.
© 2019 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Colorectal adenocarcinoma; Neuroendocrine carcinoma; Neuroendocrine marker-positive cells; Neuroendocrine tumor

Mesh:

Substances:

Year:  2019        PMID: 31390635      PMCID: PMC6888884          DOI: 10.1159/000501521

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  16 in total

1.  Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis.

Authors:  Hammad Shafqat; Shihab Ali; Mohammed Salhab; Adam J Olszewski
Journal:  Dis Colon Rectum       Date:  2015-03       Impact factor: 4.585

2.  Mixed adenoneuroendocrine carcinoma of gastrointestinal tract: report of two cases.

Authors:  Simona Gurzu; Zoltan Kadar; Tivadar Bara; Tivadar Bara; Adrian Tamasi; Leonard Azamfirei; Ioan Jung
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

3.  Mixed adenoneuroendocrine carcinoma of the colon: molecular pathogenesis and treatment.

Authors:  Leen Vanacker; Dominiek Smeets; Anne Hoorens; Erik Teugels; Roberto Algaba; Marie Françoise Dehou; Ann De Becker; Diether Lambrechts; Jacques De Greve
Journal:  Anticancer Res       Date:  2014-10       Impact factor: 2.480

4.  Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas.

Authors:  Moritz Jesinghaus; Björn Konukiewitz; Gisela Keller; Matthias Kloor; Katja Steiger; Magdalena Reiche; Roland Penzel; Volker Endris; Ruza Arsenic; Gratiana Hermann; Albrecht Stenzinger; Wilko Weichert; Nicole Pfarr; Günter Klöppel
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

Review 5.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

6.  Neuroendocrine cancers of the colon and rectum. Results of a ten-year experience.

Authors:  T J Saclarides; D Szeluga; E D Staren
Journal:  Dis Colon Rectum       Date:  1994-07       Impact factor: 4.585

7.  Neuroendocrine differentiation in colorectal carcinomas.

Authors:  U Syversen; T Halvorsen; R Mårvik; H L Waldum
Journal:  Eur J Gastroenterol Hepatol       Date:  1995-07       Impact factor: 2.566

8.  Chromogranin A expression in normal and malignant human tissues.

Authors:  L J Helman; A F Gazdar; J G Park; P S Cohen; J D Cotelingam; M A Israel
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

9.  Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases.

Authors:  Raymond Karkouche; Jean-Baptiste Bachet; Jeremy Sandrini; Emmanuel Mitry; Christophe Penna; Jean-François Côté; Hélène Blons; Frédérique Penault-Llorca; Philippe Rougier; Jean-Paul Saint André; Jean-François Emile
Journal:  Eur J Gastroenterol Hepatol       Date:  2012-12       Impact factor: 2.566

10.  A Case of Gastric Cancer with Neuroendocrine Carcinoma, Signet Ring Cell Carcinoma Components, and Intramural Metastases.

Authors:  Keishiro Aoyagi; Junya Kizaki; Taro Isobe; Yoshito Akagi
Journal:  Am J Case Rep       Date:  2016-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.